Dr. Michele L. Basche, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 705
Licensed in Colorado since 1998, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of California, San Francisco School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license DR.0037127 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hca-Healthone DBA Swedish Medical Center Englewood, CO
- The Medical Center of Aurora & South Hospital Aurora, CO
- Sky Ridge Medical Center Lone Tree, CO
- HCA Healthone Rose Denver, CO
- HCA Healthone Presbyterian St. Lukes Denver, CO
Medical groups
- Rocky Mountain Cancer Centers LLP (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 705
- Services billed
- 118,222
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 13,200 | 30 |
| Injection, pembrolizumab, 1 mg | 7,400 | 13 |
| Injection, iron sucrose, 1 mg | 5,500 | 14 |
| Injection, denosumab, 1 mg | 3,060 | 25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,080 | 62 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1,876 | 14 |
| Injection, fulvestrant, 25 mg | 1,150 | 20 |
| Injection, palonosetron hcl, 25 mcg | 1,100 | 38 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 701 | 200 |
| Carcinoembryonic antigen (cea) protein level | 666 | 274 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Denver, CO | 483 |
| Letrozole Other prescribers in Denver, CO | 170 |
| Tamoxifen Citrate Other prescribers in Denver, CO | 167 |
| Trazodone Hcl Other prescribers in Denver, CO | 80 |
| Gabapentin Other prescribers in Denver, CO | 76 |
| Ondansetron Hcl Other prescribers in Denver, CO | 53 |
| Exemestane | 53 |
| Eliquis (apixaban) Other prescribers in Denver, CO | 52 |
| Oxybutynin Chloride Other prescribers in Denver, CO | 37 |
| Citalopram Hbr (citalopram hydrobromide) Other prescribers in Denver, CO | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $18.74 in total to this clinician.
| AbbVie Inc. | $18.74 |
|---|
| Food and Beverage | $18.74 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,000 in research payments for these studies, mostly to the institutions running them.
- The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.